| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7ab29a268ba8f1a7a56981765bf46edb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P39-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-616
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-00 |
| filingDate |
2020-08-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_495f2b1869b60fa53cdb67384dd589c0 |
| publicationDate |
2021-02-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021032212-A1 |
| titleOfInvention |
Anti-aging medicine d/a targeting aging cells in tissue microenvironment and use thereof |
| abstract |
Provided are a pharmaceutical composition comprising dasatinib and aspirin and a cartridge or kit thereof and the use thereof. The pharmaceutical composition can down-regulate or eliminate natural aging cells or damaged cells, thereby prolonging the survival period of an organism. |
| priorityDate |
2019-08-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |